AstraZeneca and the ̽»¨Ö±²¥ of Cambridge today announced three new joint schemes to support more than 80 PhD scholarships and eight clinical lectureships over the next five years spanning translational science, basic and clinical research. Two of the schemes are co-funded by the NIHR Cambridge Biomedical Research Centre, a partnership between Cambridge ̽»¨Ö±²¥ Hospitals and ̽»¨Ö±²¥ of Cambridge.
Restoring the low levels of the chemical serotonin may help improve brain function and reduce impulsivity in some dementia patients, according to Cambridge researchers. A study published in the July edition of the journal Brain suggests a potential new treatment for people affected by frontotemporal dementia.
A protein that targets the effects of a faulty gene could offer the first treatment targeting the major genetic cause of pulmonary arterial hypertension, according to research funded by the British Heart Foundation (BHF) and carried out at the ̽»¨Ö±²¥ of Cambridge.
When is a rare disease not a rare disease? ̽»¨Ö±²¥answer: when big data gets involved. An ambitious new research project aims to show patients that they are not alone.
A dramatic video has captured the behaviour of cytotoxic T cells – the body’s ‘serial killers’ – as they hunt down and eliminate cancer cells before moving on to their next target.
New research suggests it may be possible to predict an infant’s progress following surgery for congenital heart disease by analysing a number of important small molecules in the blood.
̽»¨Ö±²¥first natural birth to a mother with diabetes who has been fitted with an artificial pancreas took place this week. ̽»¨Ö±²¥device has been developed by researchers at the ̽»¨Ö±²¥ of Cambridge.
Researchers have identified how proteins that play a key role in Alzheimer’s disease are linked in a pathway that controls its progression, and that drugs targeting this pathway may be a potential new way of treating the disease.
Inflammation – the body’s response to damaging stimuli – may have a protective effect against cardiovascular disease, according to a study published today in the journal Lancet Diabetes and Endocrinology.
Alzheimer’s Research UK, the world’s largest dedicated dementia research charity, has announced a £30 million Drug Discovery Alliance, launching three flagship Drug Discovery Institutes at the Universities of Cambridge, Oxford and UCL ( ̽»¨Ö±²¥ College London). ̽»¨Ö±²¥Drug Discovery Institutes will see 90 new research scientists employed in state-of-the-art facilities to fast-track the development of new treatments for Alzheimer’s disease and other dementias.
© 2025 ̽»¨Ö±²¥ of Cambridge